期刊簡介預(yù)計審稿時間：

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

轉(zhuǎn)化癌癥研究 (Transl Cancer Res TCR；印刷 ISSN：2218-676X；在線 ISSN 2219-6803；http://tcr.amegroups.com/) 是一本開放獲取、同行評審的期刊，收錄于科學引文索引擴展版 (SCIE)。TCR 發(fā)表新型治療干預(yù)的實驗室研究以及評估癌癥新治療模式的臨床試驗；新型研究調(diào)查的結(jié)果，這些調(diào)查將實驗室和臨床環(huán)境連接起來，包括風險評估、細胞和分子表征、人類癌癥的預(yù)防、檢測、診斷和治療，總體目標是改善癌癥患者的臨床護理。TCR 的重點是原創(chuàng)的、同行評審的、基于科學的研究，這些研究成功地推動了臨床醫(yī)學朝著改善患者生活質(zhì)量的目標發(fā)展。編輯和由科學家、臨床科學家以及其他專家組成的國際顧問團將確保 TCR 文章達到高質(zhì)量標準。我們接受原創(chuàng)文章以及評論文章、社論和簡短文章。

《Translational Cancer Research》(轉(zhuǎn)化癌癥研究)編輯部通訊方式為FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, PEOPLES R CHINA, HONG KONG, 00000。如果您需要協(xié)助投稿或潤稿服務(wù)，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務(wù)十年，熟悉發(fā)表政策，可為您提供一對一投稿指導，避免您在投稿時頻繁碰壁，節(jié)省您的寶貴時間，有效提升發(fā)表機率，確保SCI檢索（檢索不了全額退款）。我們視信譽為生命，多方面確保文章安全保密，在任何情況下都不會泄露您的個人信息或稿件內(nèi)容。